{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:17:42Z","timestamp":1790331462488,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2024-13-55"],"award-info":[{"award-number":["320.6750.2024-13-55"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lung cancer is the leading cause of cancer-related mortality globally, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. For resectable early-stage NSCLC, surgery and adjuvant chemotherapy remain the standard treatments, but the recurrence rate is high, and long-term survival outcomes are suboptimal. In recent years, immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized the treatment of advanced NSCLC and is gradually being extended to early-stage disease. Neoadjuvant immunotherapy, as an emerging strategy, aims to activate anti-tumor immune responses preoperatively, eliminate microscopic metastases, and downstage tumors, thereby improving surgical resectability and enhancing long-term survival for patients. Several clinical trials have demonstrated that neoadjuvant immunotherapy, either alone or in combination with chemotherapy, significantly increases the major pathological response (MPR) and pathological complete response (pCR) rates, translating into improvements in event-free survival (EFS). However, this promising therapeutic approach faces numerous challenges, including the lack of precise biomarkers for efficacy prediction, unclear treatment strategies for patients with driver gene-positive tumors, primary and secondary resistance, management of immune-related adverse events (irAEs), and the complexities of post-treatment efficacy evaluation. This review aims to comprehensively summarize the latest clinical evidence on neoadjuvant immunotherapy for lung cancer, delve into the main challenges and opportunities encountered in clinical practice, and explore its future directions, including novel combination therapies, personalized treatment strategies, and the application of innovative technologies, with the goal of optimizing clinical management for early-stage lung cancer patients and advancing research in this field.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1752298","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:45:33Z","timestamp":1769582733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Neoadjuvant immunotherapy for lung cancer: current limitations and future prospects"],"prefix":"10.3389","volume":"17","author":[{"given":"Kunpeng","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology Surgery II, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]},{"name":"School of Clinical Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Surgery II, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Surgery II, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyun","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Surgery II, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglun","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Surgery II, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Surgery II, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Surgery II, Jilin Cancer Hospital","place":["Changchun, Jilin, China"]},{"name":"School of Clinical Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092715","article-title":"Revolutionizing localized lung cancer treatment: neoadjuvant chemotherapy plus immunotherapy for all","volume":"13","author":"Ferrari","year":"2024","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1063183","article-title":"Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone","volume":"13","author":"Tang","year":"2023","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00577-5","article-title":"The cutting-edge progress of immune-checkpoint blockade in lung cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/cac2.12153","article-title":"Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art","volume":"41","author":"Kang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2641","article-title":"The promise of neoadjuvant immunotherapy and surgery for cancer treatment","volume":"25","author":"O\u2019Donnell","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005036","article-title":"Neoadjuvant immunotherapy of locoregionally advanced solid tumors","volume":"10","author":"Tarhini","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5276","article-title":"Rapid advances in resectable non-small cell lung cancer: A narrative review","volume":"10","author":"West","year":"2024","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"104080","DOI":"10.1016\/j.critrevonc.2023.104080","article-title":"Neoadjuvant therapy in non-small cell lung cancer","volume":"190","author":"Grant","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411849","article-title":"Neoadjuvant immunotherapy: A promising new standard of care","volume":"24","author":"Boydell","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00276","article-title":"SAKK 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-A multicenter single-arm phase II trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70211","article-title":"Efficacy and Safety of Neoadjuvant Immunotherapy plus Chemotherapy versus Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer Treatment: A Mixed Method Meta-Analysis Based on Global Randomized Controlled Trials","volume":"6","author":"Li","year":"2025","journal-title":"MedComm (2020)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1286104","article-title":"Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges","volume":"13","author":"Kalvapudi","year":"2023","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S437911","article-title":"Comparative efficacy and safety of neoadjuvant immunotherapy with chemotherapy versus chemotherapy alone in non-small cell lung cancer: A propensity score and inverse probability treatment weighting analysis","volume":"12","author":"Zhao","year":"2023","journal-title":"Immunotargets Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2021.02.014","article-title":"Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment","volume":"154","author":"Weissferdt","year":"2021","journal-title":"Lung Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu","year":"2023","journal-title":"Genome Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2022.0407","article-title":"Tumor immune microenvironment and immunotherapy in non-small cell lung cancer: update and new challenges","volume":"13","author":"Xing","year":"2022","journal-title":"Aging Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1053\/j.semtcvs.2020.12.012","article-title":"Systematic review of neoadjuvant immunotherapy for patients with non-small cell lung cancer","volume":"33","author":"Cao","year":"2021","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2020.05.119","article-title":"Perioperative considerations for neoadjuvant immunotherapy in non-small cell lung cancer","volume":"160","author":"Stiles","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.07.002","article-title":"Clinical utility of tumor-naive presurgical circulating tumor DNA detection in early-stage NSCLC","volume":"19","author":"Hong","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02683-0","article-title":"Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing","volume":"30","author":"Kobayashi","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000974","article-title":"Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma","volume":"8","author":"Thompson","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3892\/ol.2025.14904","article-title":"Identification and validation of a novel signature based on immune\u2212related genes from epithelial cells to predict prognosis and treatment response in patients with lung squamous cell cancer by integrated analysis of single\u2212cell and bulk RNA sequencing","volume":"29","author":"Wu","year":"2025","journal-title":"Oncol Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1654573","article-title":"Immunoproteasome components LMP2, PSME1, and PSME2 as novel tissue biomarkers predicting response and survival in neoadjuvant chemoimmunotherapy for resectable NSCLC","volume":"16","author":"Xie","year":"2025","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.673042","article-title":"Fluorescent multiplex immunohistochemistry coupled with other state-of-the-art techniques to systematically characterize the tumor immune microenvironment","volume":"8","author":"Boisson","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13046-023-02697-y","article-title":"Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer","volume":"42","author":"He","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000496","article-title":"Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis","volume":"109","author":"Chen","year":"2023","journal-title":"Int J Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-584","article-title":"A narrative review of pathologic response in non-small cell lung cancer: challenges, implications, and future directions","volume":"14","author":"Li","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2024.670","article-title":"Histological assessment and interobserver agreement in major pathologic response for non-small cell lung cancer with neoadjuvant therapy","volume":"57","author":"Kim","year":"2025","journal-title":"Cancer Res Treat"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2983","article-title":"Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade","volume":"31","author":"Rosner","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"102724","DOI":"10.1016\/j.ctrv.2024.102724","article-title":"Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer","volume":"126","author":"Grant","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1038\/s41598-022-07423-w","article-title":"The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy","volume":"12","author":"Su","year":"2022","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cac2.12505","article-title":"Management of locally advanced non-small cell lung cancer: State of the art and future directions","volume":"44","author":"Miao","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"111281","DOI":"10.1016\/j.isci.2024.111281","article-title":"Adjuvant treatment after neoadjuvant immunotherapy in patients with non-small cell lung cancer","volume":"27","author":"Zhao","year":"2024","journal-title":"iScience"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15247","article-title":"Subsequent surgical treatment or maintenance immunotherapy in stage III lung cancer patients achieving a favorable response following neoadjuvant immunotherapy: A matched retrospective cohort study from the surgical perspective","volume":"15","author":"Dai","year":"2024","journal-title":"Thorac Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2021.02.08","article-title":"Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer","volume":"33","author":"Guo","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21552","article-title":"Artificial intelligence in cancer imaging: Clinical challenges and applications","volume":"69","author":"Bi","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0583","article-title":"Facts and hopes in neoadjuvant immunotherapy: current approvals and emerging evidence","volume":"30","author":"Vaidya","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1752298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:14:54Z","timestamp":1771924494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1752298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1752298"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1752298","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"article-number":"1752298"}}